超难治性精神分裂症患者的谷氨酸能神经代谢物水平:一项横断面3T质子磁共振波谱研究
该横断面研究用3T质子磁共振波谱比较了超难治性、氯氮平响应性难治性、非难治性精神分裂症患者及健康对照的谷氨酸能神经代谢物水平。共纳入100人,发现仅背侧前扣带回谷氨酸+谷氨酰胺存在组间差异,超难治性患者高于健康对照。提示前扣带回谷氨酸能代谢物升高可能是抗精神病药治疗抵抗(包括对氯氮平抵抗)的共享生物学特征之一。
要点
- 超难治性精神分裂症患者背侧前扣带回谷氨酸+谷氨酰胺水平高于健康对照。
- 尾状核与背外侧前额叶的谷氨酸能代谢物未见组间差异。
- 前扣带回谷氨酸能代谢物升高可能是治疗抵抗的共享生物学特征。
核心结论
- 背侧前扣带回谷氨酸+谷氨酰胺水平升高可能是抗精神病药治疗抵抗(包括对氯氮平抵抗)的共享生物学特征之一。
研究设计与样本
- 横断面研究,采用3T质子磁共振波谱(点解析波谱,回波时间35 ms)评估谷氨酸及谷氨酸+谷氨酰胺水平。
- 共纳入100名参与者:超难治性精神分裂症26例、非超难治性难治性精神分裂症27例、非难治性精神分裂症21例、健康对照26名。
- 在尾状核、背侧前扣带回及背外侧前额叶进行谷氨酸能神经代谢物水平的组间比较。
主要发现
- 背侧前扣带回谷氨酸+谷氨酰胺水平存在组间差异(F3,96 = 2.93,p = .038)。
- 超难治性精神分裂症患者背侧前扣带回谷氨酸+谷氨酰胺水平高于健康对照(p = .038)。
- 尾状核与背外侧前额叶的谷氨酸能神经代谢物水平未见组间差异。
临床怎么用
- 对于难治性精神分裂症患者,可关注背侧前扣带回谷氨酸能代谢物水平作为治疗抵抗的潜在生物学标记。
- 该发现支持将谷氨酸能系统作为超难治性精神分裂症治疗靶点的进一步研究。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In terms of antipsychotic treatment response, patients with schizophrenia can be classified into three groups: 1) treatment resistant to both non-clozapine (non-CLZ) antipsychotics and CLZ (ultra-treatment-resistant schizophrenia [URS]), 2) treatment resistant to non-CLZ antipsychotics but CLZ-responsive schizophrenia [non-URS]), and 3) responsive to first-line antipsychotics (non-treatment-resistant schizophrenia). This study aimed to compare glutamatergic neurometabolite levels among these three patient groups and healthy control subjects using proton magnetic resonance spectroscopy. METHODS: Glutamate and glutamate+glutamine levels were assessed in the caudate, the dorsal anterior cingulate cortex (dACC), and the dorsolateral prefrontal cortex using 3T proton magnetic resonance spectroscopy (point-resolved spectroscopy, echo time = 35 ms). Glutamatergic neurometabolite levels were compared between the groups. RESULTS: A total of 100 participants were included, consisting of 26 patients with URS, 27 patients with non-URS, 21 patients with non-treatment-resistant schizophrenia, and 26 healthy control subjects. Group differences were detected in ACC glutamate+glutamine levels (F3,96 = 2.93, p = .038); patients with URS showed higher dACC glutamate+glutamine levels than healthy control subjects (p = .038). There were no group differences in the caudate or dorsolateral prefrontal cortex. CONCLUSIONS: Taken together with previous studies that demonstrated higher ACC glutamate levels in patients with treatment-resistant schizophrenia, this study suggests that higher levels of ACC glutamatergic metabolites may be among the shared biological characteristics of treatment resistance to antipsychotics, including CLZ.
引用
- Iwata Y, Nakajima S, Plitman E, et al. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry. 2018. PMID: 30389132. doi:10.1016/j.biopsych.2018.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。